Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills

5 april 2013 uppdaterad av: Dawn Velligan, The University of Texas Health Science Center at San Antonio

Do Patients Taking Aripiprazole Learn More in Vocational Skills Training Than Patients Taking Olanzapine?

STUDY PURPOSE: To study whether patients who have schizophrenia or schizoaffective disorder and are randomly assigned to switch to aripiprazole prior to participation in a brief vocational skills training (VST) will have improved cognitive functioning and learn more in VST than those randomly assigned to stay on olanzapine. There is evidence that VST is important in improving role functioning for schizophrenia patients, however, cognitive impairments limit the ability of some patients to benefit from skills training approaches. Patients switched from olanzapine to aripiprazole improve in terms of verbal learning and verbal learning has been shown to be a strong predictor of community outcome. It is unclear whether the cognitive benefits of switching to aripiprazole extend to improve learning of vocational skills.

Studieöversikt

Status

Avslutad

Intervention / Behandling

Detaljerad beskrivning

Many schizophrenia outpatients have cognitive deficits and poor vocational functioning. There is evidence from randomized controlled trials that vocational skills training is important in improving vocational role functioning for schizophrenia patients. However, it has become clear that cognitive impairments limit the ability of patients to benefit from skills training approaches. Recent research demonstrates that patients switched from olanzapine to aripiprazole improve in terms of verbal learning. Verbal learning has been found to be a strong predictor of multiple domains of community outcome. It is unclear whether the cognitive benefits of switching to aripiprazole extend to improve learning of vocational skills. This study examines whether aripiprazole can improve the ability to benefit from expensive rehabilitation programs focused on skill-building. Specifically, the study examines whether patients who switch from olanzapine to aripiprazole learn more and benefit more from a brief vocational skills program than patients who remain on olanzapine. Specific aims are as follows: (1) we hypothesize that patients on aripiprazole will demonstrate better scores on tests of cognitive functioning following twelve weeks of medication treatment than patients on olanzapine and (2) we hypothesize that patients on aripiprazole will have significantly higher scores on vocational performance following a brief (2-day) vocational training and assessment session than those on olanzapine. Furthermore, we hypothesize that these gains will be maintained following one week of non-exposure to the trained vocational tasks.

Studietyp

Interventionell

Inskrivning (Faktisk)

43

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Texas
      • San Antonio, Texas, Förenta staterna, 78229
        • The University of Texas Health Science Center at San Antonio

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 52 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • DSM-IV diagnosis of schizophrenia or schizoaffective disorder
  • Between ages of 18 and 52
  • On olanzapine for a minimum of 3 months prior to participation
  • Outpatient status for at least 3 months
  • Vision and hearing intact or corrected to extent that will allow participation in vocational training and cognitive testing
  • Score in impaired range on at least one test from a cognitive battery designed to be sensitive to impairments in schizophrenia
  • Ability to participate in the informed consent process, as evidenced by an assessment of the capacity to give consent for research developed by the Maryland Psychiatric Research Center (DeRenzo et al., 1998).

Exclusion Criteria:

  • History of head injury, mental retardation or neurological disorder
  • Below a 4th grade reading level (32) according to the WRAT-3
  • Taking multiple atypical antipsychotics
  • Taking any decanoate antipsychotic
  • Hospitalization in last 3 months
  • Employment
  • Alcohol or drug abuse that interferes with functioning or medication compliance

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vad mäter studien?

Primära resultatmått

Resultatmått
Toilet Tank Assembly Task at 13 and 14 weeks
Card Sorting Task at baseline, 13 and 14 weeks

Sekundära resultatmått

Resultatmått
Brief Psychiatric Rating Scale at baseline and 13 week
Negative Symptom Assessment at baseline and 13 week
Global Assessment of Functioning Scale at baseline and 13 week
Social and Occupational Functioning Scale at baseline and 13 week
Work portion of Test of Adaptive Behaviors in Schizophrenia at baseline and 13 week
STAN neurocognitive tests at baseline and 13 week
Trails A at baseline and 13 week
Trails Aa at baseline and 13 week
Trails B at baseline and 13 week

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Dawn I Velligan, Ph.D., University of Texas Health Science Center in San Antonio
  • Studierektor: Mary D. Woolsey, M.S., The University of Texas Health Science Center at San Antonio

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 januari 2004

Primärt slutförande (Faktisk)

1 juni 2007

Avslutad studie (Faktisk)

1 juni 2007

Studieregistreringsdatum

Först inskickad

13 september 2005

Först inskickad som uppfyllde QC-kriterierna

13 september 2005

Första postat (Uppskatta)

22 september 2005

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

8 april 2013

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 april 2013

Senast verifierad

1 april 2013

Mer information

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på aripiprazol

3
Prenumerera